All In Biotech

Drug Trial Radar · NCT03915366

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 563 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

563

Actual

Start

Mar 1, 2020

Primary completion

Jan 31, 2025

Study completion Jan 31, 2025

Sponsor

Lead sponsor
Hospital Universitario 12 de OctubreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Bordeaux; Institut National de la Santé Et de la Recherche Médicale, France; PENTA Foundation; Centre Hospitalier Cocody; Malawi-Liverpool-Wellcome Trust Clinical Research Programme; Eduardo Mondlane University; Centro de Investigação em Saúde de Manhiça; Stichting Katholieke Universiteit; Barcelona Institute for Global Health; University of Lincoln; Makerere University; University Teaching Hospital, Lusaka, Zambia; University of Zimbabwe; Kamuzu Central Hospital; Servicio Madrileño de Salud, Madrid, Spain
First posted
Apr 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 28 days, up to 365 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.

Conditions

  • Pneumonia
  • HIV/AIDS
  • Tuberculosis
  • Cytomegalovirus Infections

Interventions

  • Valganciclovir Oral Solution [Valcyte]Drug

    Treatment for CMV

  • Tuberculostatic AgentsDrug

    Treatment for tuberculosis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 1 year

Locations

13 sites in 11 countries. Site status is shown where the registry gives one.

  • Programme PACCI. Centre Hospitalier Cocody.

    Abidjan, Côte d’Ivoire

  • Université de Bourdeaux

    Bourdeaux, France

  • INSERM

    Toulouse, France

  • PENTA Foundation

    Padova, Italy

  • Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine

    Blantyre, Malawi

  • Cemtro de Investigaçao em Saúde da Manhiça

    Manhiça, Mozambique

  • Hospital Central Maputo

    Maputo, Mozambique

  • Stichting Katholieke Universiteit Radboudumc

    Nijmegen, Netherlands

  • Fundación para la Investigación Biomédica del Hospital 12 de Octubre

    Madrid, Spain

  • Makerere University - Mulago Hospital

    Kampala, Uganda

  • University of Lincoln

    Lincoln, United Kingdom

  • Lusaka Teaching Hospital

    Lusaka, Zambia

  • University of Zimbabwe Clinical Research Centre

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.